<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Becton Dickinson Company</title>
	<atom:link href="http://www.stockbloghub.com/tag/becton-dickinson-company/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BDX) Becton, Dickinson and Company Hikes Dividend</title>
		<link>http://www.stockbloghub.com/2011/11/30/bdx-becton-dickinson-and-company-hikes-dividend/87707</link>
		<comments>http://www.stockbloghub.com/2011/11/30/bdx-becton-dickinson-and-company-hikes-dividend/87707#comments</comments>
		<pubDate>Wed, 30 Nov 2011 19:46:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87707</guid>
		<description><![CDATA[Becton, Dickinson and Company (BDX) recently declared a quarterly dividend of 45 cents for each common share, representing a hike of 4 cents, or approximately 10%, from the preceding quarter. The company will make the dividend payment on December 30, 2011, to its shareholders of record, as of December 12, 2011. The new quarterly dividend represents an annualized outflow of $1.80 per share. Becton noted its robust record of creating shareholder value partly by returning funds to its shareholders. The current quarter heralds the 40th straight quarter in which the company has hiked its dividend payment. The company’s dividend track record indicates its confidence in its strategy as well as long-term outlook. Becton Dickinson forecasts revenues will increase 1% to 3% (or 2% to 4% in constant currency) for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/bdx-becton-dickinson-and-company-hikes-dividend/87707/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Technology Industry Stock Outlook &#8211; November 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069</link>
		<comments>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069#comments</comments>
		<pubDate>Fri, 18 Nov 2011 18:52:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87069</guid>
		<description><![CDATA[The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures, reimbursement pressure and the impact of health care reform continues to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. The beleaguered U.S. implantable defibrillator market continues to bother cardiac devices makers, as reflected by sustained implant volume pressure. On the other hand, companies in the orthopedic domain remain affected by a still choppy reconstructive implant market as they faced sustained pressure across hip, knee and spine businesses in the third quarter (albeit to a lesser extent vis-à-vis the sequentially prior quarter). Although a number of these issues are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TGT) Chase Track Records If You Want to Profit</title>
		<link>http://www.stockbloghub.com/2011/09/12/tgt-chase-track-records-if-you-want-to-profit/82373</link>
		<comments>http://www.stockbloghub.com/2011/09/12/tgt-chase-track-records-if-you-want-to-profit/82373#comments</comments>
		<pubDate>Mon, 12 Sep 2011 17:18:56 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Discount Variety Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Harleysville Group Inc.]]></category>
		<category><![CDATA[HCP]]></category>
		<category><![CDATA[HCP Inc.]]></category>
		<category><![CDATA[HGIC]]></category>
		<category><![CDATA[Kinder Morgan Energy Partners LP]]></category>
		<category><![CDATA[KMP]]></category>
		<category><![CDATA[LANC]]></category>
		<category><![CDATA[Lancaster Colony Corporation]]></category>
		<category><![CDATA[LOW]]></category>
		<category><![CDATA[Lowe's Companies Inc.]]></category>
		<category><![CDATA[T. Rowe Price Group Inc.]]></category>
		<category><![CDATA[Target Corporation]]></category>
		<category><![CDATA[TGT]]></category>
		<category><![CDATA[TROW]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82373</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 31, 2011: Issue #1590 Perhaps because I have time on my side, I get excited when the market sells off like it did a few weeks ago. I know that I’ll be able to buy quality stocks at a lower price. That’s especially interesting to income investors who might be able to pick up an extra half a percentage point or so of yield with no real changes to a company’s ability to generate cash. When stocks decline, one of the first places I look is the list of S&#38;P Dividend Aristocrats. Dividend Aristocrats are stocks that are members of the S&#38;P 500 that have increased their dividends every year for the past 25 years. And their track records are welcome ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/12/tgt-chase-track-records-if-you-want-to-profit/82373/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Outlook &#8211; Sept. 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743</link>
		<comments>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743#comments</comments>
		<pubDate>Thu, 08 Sep 2011 19:53:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82743</guid>
		<description><![CDATA[June quarter results mostly mirror the preceding quarter as a host of macro headwinds (including price and procedure volume pressures) continued to haunt the MedTech industry and weighed on the performance of the incumbent players. Although a number of these issues are expected to linger over the second-half of 2011, the industry is expected to fare relatively better this year thanks to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest market, with estimated sales of roughly $95 billion in 2010. The highly-regulated medical devices industry is divided into different segments including Cardiology, Oncology, Neuro, Orthopedic and Aesthetic Devices. The U.S. medical devices ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CFN) CareFusion Buying Rowa for $150 Million</title>
		<link>http://www.stockbloghub.com/2011/07/12/cfn-carefusion-buying-rowa-for-150-million/78859</link>
		<comments>http://www.stockbloghub.com/2011/07/12/cfn-carefusion-buying-rowa-for-150-million/78859#comments</comments>
		<pubDate>Tue, 12 Jul 2011 16:57:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78859</guid>
		<description><![CDATA[Medical technology company CareFusion Corporation (CFN) recently made a deal to buy German medication storage systems maker Rowa GmbH for roughly $150 million. Rowa, which has customers in 30 countries, specializes in high-speed robotic medication storage and retrieval systems for retail and hospital pharmacies. The company has deployed more than 3,500 automation systems in retail and hospital pharmacies and added 500 new customers last year. In addition to its stronghold in Germany, Rowa has operations in Italy, the Netherlands, Denmark and Sweden. The company’s installations climbed 9% in 2010 and it expanded product sales into Australia, Canada and other new markets during the year. Rowa&#8217;s automated systems, which are used to store and retrieve packaged pharmaceutical inventories, are geared to cut costs and improve workflow. Its products and technologiesare complementary ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/12/cfn-carefusion-buying-rowa-for-150-million/78859/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Presents Sustainability Report</title>
		<link>http://www.stockbloghub.com/2011/07/05/bax-baxter-international-presents-sustainability-report/78364</link>
		<comments>http://www.stockbloghub.com/2011/07/05/bax-baxter-international-presents-sustainability-report/78364#comments</comments>
		<pubDate>Wed, 06 Jul 2011 00:10:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78364</guid>
		<description><![CDATA[Baxter International (BAX) recently presented its 2010 Sustainability Report. This was the 12th straight year in which the company has reported on its economic, social and environmental outcomes. This report highlights the company’s progress toward its sustainability goals and its determination to counter challenges to global sustainability through a number of measures. The initiatives mentioned in the 2010 report include efforts to cut down on emission of green house gas, reduce water usage and outlay almost $80 million from The Baxter International Foundation to address urgent worldwide causes. Baxter’s sustainability goals reflect issues of critical concern to the company and areas where it is well positioned to make a favorable impact. Each priority area is linked with long-term performance goals to aid measurement of progress. The company’s sustainability priorities include ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/bax-baxter-international-presents-sustainability-report/78364/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Unilife Completes Validation Tests</title>
		<link>http://www.stockbloghub.com/2011/07/01/bdx-unilife-completes-validation-tests/78155</link>
		<comments>http://www.stockbloghub.com/2011/07/01/bdx-unilife-completes-validation-tests/78155#comments</comments>
		<pubDate>Fri, 01 Jul 2011 16:39:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78155</guid>
		<description><![CDATA[Retractable syringes maker Unilife Corporation (UNIS) has successfully completed all the required validation tests for its Unifill ready-to-fill (prefilled) syringe, representing the final step in the industrialization process of this unique device. The achievement underscores that the Unifill syringe is fully compliant with all major regulatory requirements and meets the company’s own standards for device quality, reliability and functionality. Unilife began initial production of the Unifill syringe at its FDA-approved plant located in York, Pennsylvania, in late March 2011. The company is currently in the process of negotiating with more than 20 pharmaceutical companies who have shown interest in its syringe. It is anticipated that these pharmaceutical makers will buy from the early production lots, in order to conduct their own formal appraisal of the Unifill syringe in combination with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/bdx-unilife-completes-validation-tests/78155/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Gets Favorable Opinion for Drug</title>
		<link>http://www.stockbloghub.com/2011/06/29/bax-baxter-international-gets-favorable-opinion-for-drug/77640</link>
		<comments>http://www.stockbloghub.com/2011/06/29/bax-baxter-international-gets-favorable-opinion-for-drug/77640#comments</comments>
		<pubDate>Wed, 29 Jun 2011 17:04:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77640</guid>
		<description><![CDATA[Baxter International (BAX) recently revealed that the Committee for Medicinal Products for Human Use (“CHMP”) belonging to the European Medicines Agency (“EMA”) has given a favorable opinion for extending the therapeutic indications of Kiovig to encompass a new indication for multifocal motor neuropathy (“MMN”), a debilitating disorder needing life-time therapy. Following acceptance by the European Commission, Baxter will be granted marketing authorization for the Kiovig MMN indication across all European Union (“EU”) nations. MMN is an uncommon autoimmune disorder marked by gradual weakening of the limbs. The victim faces difficulty performing simple tasks. If left untreated, MMN may degenerate into muscle atrophy or involuntary twitching. The favorable opinion for Kiovig MMN is underpinned by a couple of open-label, investigator-initiated prospective clinical efficacy studies on victims of MMN, both of which ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/bax-baxter-international-gets-favorable-opinion-for-drug/77640/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179</link>
		<comments>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:09:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77179</guid>
		<description><![CDATA[A host of macro headwinds (including price and procedure volume pressure) which hit the MedTech industry last year continued to haunt the sector during the March quarter and encumber growth. Although a number of these issues are expected to linger through the remainder of 2011, the industry is expected to fare relatively better this year thanks to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest market, with estimated sales of roughly $95 billion in 2010. The medical devices industry is divided into different segments including Cardiology, Oncology, Neuro, Orthopedic and Aesthetic Devices. The U.S. medical devices industry continues to grow at a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Unilife Hosts White House Business Council Meeting</title>
		<link>http://www.stockbloghub.com/2011/06/22/bdx-unilife-hosts-white-house-business-council-meeting/77180</link>
		<comments>http://www.stockbloghub.com/2011/06/22/bdx-unilife-hosts-white-house-business-council-meeting/77180#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:05:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77180</guid>
		<description><![CDATA[Unilife Corporation (UNIS) recently hosted Kathleen Merrigan, Deputy Secretary of the U.S. Department of Agriculture (“USDA”), for a White House Business Council (“WHBC”) meeting with local business chiefs at its plant in York, Pennsylvania. The White House set up the WHBC under the leadership of President Obama. The WHBC is currently holding “The Winning the Future Roundtables” with American Business tour, which permits the Obama Administration to directly communicate with the captains of industry. U.S. business leaders are able to voice their opinion on matters such as how to promote economic growth, place Americans in jobs and create a better future. The WHBC discussion, promoted by Unilife, is among the initial encounters among a series of roundtable meetings. It is estimated that over 100 Council roundtables will be organized by ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/bdx-unilife-hosts-white-house-business-council-meeting/77180/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VIVO) FDA OKs Meridian C. Difficile Test</title>
		<link>http://www.stockbloghub.com/2011/05/13/vivo-fda-oks-meridian-c-difficile-test/74020</link>
		<comments>http://www.stockbloghub.com/2011/05/13/vivo-fda-oks-meridian-c-difficile-test/74020#comments</comments>
		<pubDate>Fri, 13 May 2011 20:25:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Meridian Bioscience Inc.]]></category>
		<category><![CDATA[SI]]></category>
		<category><![CDATA[Siemens AG]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VIVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74020</guid>
		<description><![CDATA[Diagnostic test kit maker Meridian Bioscience (VIVO) has clinched the approval of U.S. Food and Drug Administration (“FDA”) for its new C. difficile (Clostridium difficile) test dubbed Premier C. difficile GDH. The approval of this next-generation test broadens the Cincinnati-based company’s portfolio of C. difficile tests and underscores its sustained commitment to bring out breakthrough products for the detection of C. difficile. Premier GDH has been marketed in Europe since October 2010. C. difficile is a highly drug-resistant bacterium which exists in the environment in spore (or inactive) form and produces a toxin that causes diarrhea and more serious intestinal conditions such as colitis. C. difficile spores are frequently found in hospitals, nursing homes and extended care facilities. Although spores cannot cause infection directly, they transform into the active (or ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/13/vivo-fda-oks-meridian-c-difficile-test/74020/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Company News for April 27, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/27/bdx-company-news-for-april-27-2011-corporate-summary/72544</link>
		<comments>http://www.stockbloghub.com/2011/04/27/bdx-company-news-for-april-27-2011-corporate-summary/72544#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:30:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Central European Media Enterprises Limited]]></category>
		<category><![CDATA[CETV]]></category>
		<category><![CDATA[CH Robinson Worldwide Inc.]]></category>
		<category><![CDATA[CHRW]]></category>
		<category><![CDATA[F]]></category>
		<category><![CDATA[Ford Motor Company]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[JCI]]></category>
		<category><![CDATA[Johnson Controls Inc.]]></category>
		<category><![CDATA[LMT]]></category>
		<category><![CDATA[Lockheed Martin Corporation]]></category>
		<category><![CDATA[Mission West Properties Inc]]></category>
		<category><![CDATA[MSW]]></category>
		<category><![CDATA[Timken Company]]></category>
		<category><![CDATA[TKR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72544</guid>
		<description><![CDATA[•    Hospira (NYSE:HSP) reported Q1 EPS of $0.93, well ahead of the Zacks Consensus Estimate of $0.78 per share. Revenues for the quarter fell less by than a percent to $1.0 billion, topping the Zacks Consensus Estimate of $941.0 million •    Ford (NYSE:F) reported Q1 EPS of $0.61, beating the Zacks Consensus Estimate of $0.50 per share. Revenues for the quarter rose 17.8% year-over-year to $33.1 billion, higher than the Zacks Consensus Estimate of $30.188 billion •    Lockheed Martin Corp (NYSE:LMT) reported Q1 EPS of $1.55, above the Zacks Consensus Estimate for $1.51 per share. Revenues for the quarter increased 2.9% year-over-year to $10.63 billion, slightly lower than the Zacks Consensus Estimate of $10.644 billion •    Bearings and specialty steel manufacturer The Timken Co. (NYSE:TKR) raised its full year 2011 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/bdx-company-news-for-april-27-2011-corporate-summary/72544/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Launches Fresh Initiative To Mark World Hemophilia Day</title>
		<link>http://www.stockbloghub.com/2011/04/14/bax-baxter-international-launches-fresh-initiative-to-mark-world-hemophilia-day/71583</link>
		<comments>http://www.stockbloghub.com/2011/04/14/bax-baxter-international-launches-fresh-initiative-to-mark-world-hemophilia-day/71583#comments</comments>
		<pubDate>Thu, 14 Apr 2011 22:23:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71583</guid>
		<description><![CDATA[To mark World Hemophilia Day, Baxter International (BAX) recently reiterated its determination to maintain the standard of care and ensure adequate access to treatment for victims of hemophilia and other bleeding disorders. The company is extending its hand to the World Federation of Hemophilia (“WFH”) to start Advocacy in Action, a creative, multi-year project to assist nations play an advocacy role for victims of bleeding disorders. Baxter is funding this initiative with a grant. Furthermore, Advocacy in Action’s role is intertwined with the WFH theme for World Hemophilia Day, which is “Be Inspired, Get Involved in Treatment for All”. Since its inception, in honor of Frank Schnabel in 1989, World Hemophilia Day (observed on April 17) has played a key role in heightening awareness of hemophilia and various bleeding problems. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/14/bax-baxter-international-launches-fresh-initiative-to-mark-world-hemophilia-day/71583/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COV) Covidien&#8217;s Pipeline Device Cleared</title>
		<link>http://www.stockbloghub.com/2011/04/13/cov-covidiens-pipeline-device-cleared/71004</link>
		<comments>http://www.stockbloghub.com/2011/04/13/cov-covidiens-pipeline-device-cleared/71004#comments</comments>
		<pubDate>Wed, 13 Apr 2011 16:30:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien plc]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71004</guid>
		<description><![CDATA[Leading healthcare products maker Covidien plc (COV) has secured Premarket Approval (“PMA”) from the U.S. Food and Drug Administration’s (“FDA”) for its Pipeline Embolization Device for treating adults (22 years and above) with large, giant and wide-neck cerebral aneurysms (a brain vascular disorder). The approval follows the unanimous recommendation of the FDA’s advisory panel in March 2011. Covidien obtained the Pipeline Embolization Device following its $2.6 billion acquisition of endovascular devices maker ev3 Inc in July 2010. The device has CE Mark approval in Europe and has been marketed outside the U.S. since July 2009. According to Covidien, it will be available at the existing clinical sites in the U.S. shortly. Cerebral aneurysms is a condition manifested by the dilation of blood vessels in the brain due to weakness in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/cov-covidiens-pipeline-device-cleared/71004/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Industry Outlook &#8211; April 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413</link>
		<comments>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413#comments</comments>
		<pubDate>Thu, 31 Mar 2011 23:07:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Cyberonics Inc]]></category>
		<category><![CDATA[CYBX]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[QSII]]></category>
		<category><![CDATA[Quality Systems Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[TOMO]]></category>
		<category><![CDATA[TomoTherapy Incorporated]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70413</guid>
		<description><![CDATA[Last year was challenging for medical device companies given the exigent economic conditions and an uncertain healthcare environment. The MedTech industry was hit by several macro headwinds in 2010 including price/volume and utilization pressure and a more restrictive regulatory environment. Although a number of these issues remain, the industry is expected to fare better this year due to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest medical devices market, with estimated sales of roughly $95 billion in 2010. The medical devices industry is divided into different segments such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices and Healthcare IT (“HCIT”). The U.S. medical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/31/mdt-medical-devices-industry-outlook-april-2011-industry-outlook/70413/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COV) Covidien plc Quarterly Earnings Top Expectations &#8211; Profits Skyrocket</title>
		<link>http://www.stockbloghub.com/2010/11/12/cov-covidien-plc-quarterly-earnings-top-expectations-profits-skyrocket/58778</link>
		<comments>http://www.stockbloghub.com/2010/11/12/cov-covidien-plc-quarterly-earnings-top-expectations-profits-skyrocket/58778#comments</comments>
		<pubDate>Fri, 12 Nov 2010 19:46:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien plc]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58778</guid>
		<description><![CDATA[Ireland-based health care product maker Covidien plc (COV) reported fourth-quarter fiscal 2010 (ended September 24) adjusted earnings per share of 84 cents, exceeding the Zacks Consensus Estimate of 74 cents and the year-ago earnings of 71 cents. For fiscal 2010, adjusted earnings of $3.38 per share outshone the Zacks Consensus Estimate of $3.28 and were above the corresponding year-ago figure of $2.78. Adjusted earnings exclude one-time items such as acquisition and restructuring charges, loss on divestitures and tax-related adjustments. Net income for the quarter was $443 million (or 89 cents a share), representing a staggering eightfold annualized growth. Profits were boosted by higher sales of medical devices. Moreover, the year-ago profit (of $56 million) was hit by hefty tax expenses. For fiscal 2010, net income rocketed 80% year over year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/12/cov-covidien-plc-quarterly-earnings-top-expectations-profits-skyrocket/58778/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Company News for November 4, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/11/04/bdx-company-news-for-november-4-2010-corporate-summary/58043</link>
		<comments>http://www.stockbloghub.com/2010/11/04/bdx-company-news-for-november-4-2010-corporate-summary/58043#comments</comments>
		<pubDate>Thu, 04 Nov 2010 17:42:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[BHP]]></category>
		<category><![CDATA[Bhp Billiton Limited]]></category>
		<category><![CDATA[Directv Group Inc]]></category>
		<category><![CDATA[DTV]]></category>
		<category><![CDATA[EOG]]></category>
		<category><![CDATA[Eog Resources Inc]]></category>
		<category><![CDATA[Foster Wheeler AG]]></category>
		<category><![CDATA[FWLT]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[NRG]]></category>
		<category><![CDATA[NRG Energy]]></category>
		<category><![CDATA[POT]]></category>
		<category><![CDATA[Potash Corporation of Saskatchewan Inc]]></category>
		<category><![CDATA[QCOM]]></category>
		<category><![CDATA[QUALCOMM Inc]]></category>
		<category><![CDATA[SIRI]]></category>
		<category><![CDATA[SIRIUS XM Radio Inc]]></category>
		<category><![CDATA[Time Warner Cable Inc.]]></category>
		<category><![CDATA[TWC]]></category>
		<category><![CDATA[WCG]]></category>
		<category><![CDATA[WellCare Health Plans Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58043</guid>
		<description><![CDATA[• Qualcomm (NASDAQ:QCOM) posted better-than-expected third-quarter earnings of $0.68, up from estimates of $0.59, and revenues of $2.95 billion, that beat estimates of $2.85 billion • NRG Energy (NYSE:NRG) posted a third quarter earnings and revenue miss, with results of $0.87 below estimates for $$0.89, and revenues of $2.7 billion, off 7.9% YoY shy of estimates for $3 billion • Time Warner Cable (NYSE:TWC) posted estimate-topping third quarter earnings of $1.00, versus estimates for $0.89, on a 5.2% revenue gain to $4.7 billion, inline with estimates. The firm also announced plans for a $4 billion common share buyback • Canada blocked BHP&#8217;s (NYSE:BHP) bid for Potash (NYSE:POT) yesterday • Becton Dickenson (NYSE:BDX) reported fiscal fourth quarter earnings and revenues that matched Street projections. Earnings posted at $1.24 and revenues at $1.87 billion. • WellCare (NYSE:WCG) reported ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/04/bdx-company-news-for-november-4-2010-corporate-summary/58043/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Introduces GLASSIA</title>
		<link>http://www.stockbloghub.com/2010/11/03/bax-baxter-international-introduces-glassia/56875</link>
		<comments>http://www.stockbloghub.com/2010/11/03/bax-baxter-international-introduces-glassia/56875#comments</comments>
		<pubDate>Wed, 03 Nov 2010 18:20:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56875</guid>
		<description><![CDATA[Medical products giant Baxter International (BAX) officially commenced the U.S. launch of GLASSIA Alpha 1-Proteinase inhibitor for the treatment of emphysema. The company secured exclusive marketing rights to GLASSIA in the U.S., Canada, Australia and New Zealand from Israel-based biopharmaceuticals company Kamada Ltd in August 2010. The distribution deal calls for an upfront cash payment of $20 million by Baxter to Kamada and includes a provision preventing the latter from negotiating or agreeing for distributing GLASSIA in other markets for a defined period of time. Baxter has also been granted the rights to produce the drug and secure associated regulatory approvals in the specific markets covered by the agreement. Moreover, Baxter may make additional milestone payments of up to $25 million on achievement of specific commercial and production-related landmarks and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/03/bax-baxter-international-introduces-glassia/56875/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COV) Covidien Raises Quarterly Dividend by 11%</title>
		<link>http://www.stockbloghub.com/2010/10/12/cov-covidien-raises-quarterly-dividend-by-11/54554</link>
		<comments>http://www.stockbloghub.com/2010/10/12/cov-covidien-raises-quarterly-dividend-by-11/54554#comments</comments>
		<pubDate>Tue, 12 Oct 2010 14:32:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien plc]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54554</guid>
		<description><![CDATA[Covidien plc (COV), a leading healthcare products maker, recently enhanced shareholder returns by raising its quarterly dividend by 11% to 20 cents a share from 18 cents. The revised quarterly dividend is payable on Nov 8, 2010, to shareholders of record as on Oct 4, 2010. This represents the Ireland-based company’s second dividend hike over the past 12 months. Covidien’s previous dividend increase was in September 2009, when it raised the quarterly payout by 12.5% to 18 cents a share from 16 cents. Subsequently, its Board of Directors had authorized the repurchase of shares worth up to $1 billion in March 2010. The dividend increase underscores Covidien’s commitment to deliver incremental returns to investors leveraging a solid free cash flow and strong earnings power. The company continues to maintain a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/12/cov-covidien-raises-quarterly-dividend-by-11/54554/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GPRO) Gen-Probe Files Pre-market Approval Application for Prostate Cancer Test</title>
		<link>http://www.stockbloghub.com/2010/09/26/gpro-gen-probe-files-pre-market-approval-application-for-prostate-cancer-test/52758</link>
		<comments>http://www.stockbloghub.com/2010/09/26/gpro-gen-probe-files-pre-market-approval-application-for-prostate-cancer-test/52758#comments</comments>
		<pubDate>Mon, 27 Sep 2010 05:04:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[NAT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52758</guid>
		<description><![CDATA[Diagnostic products maker Gen-Probe Inc. (GPRO) has submitted a Pre-market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis of prostate cancer. Gen-Probe is seeking FDA approval to use the assay to test urine specimens from men who earlier had a negative prostate biopsy. This represents the second of the four PMA submissions that Gen-Probe plans to complete in 2010. The FDA has formally accepted the PROGENSA PMA and has advised Gen-Probe that a meeting (timeline unspecified) of the Medical Devices Advisory Committee&#8217;s Immunology Panel will be necessary to support approval of the filling. Gen-Probe acquired the exclusive global rights to the PCA3 (a genetic marker for prostate cancer) from Canadian cancer diagnostic tests ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/26/gpro-gen-probe-files-pre-market-approval-application-for-prostate-cancer-test/52758/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(COV) Covidien Beats The Street by a Nickel</title>
		<link>http://www.stockbloghub.com/2010/07/30/cov-covidien-beats-the-street-by-a-nickel/45401</link>
		<comments>http://www.stockbloghub.com/2010/07/30/cov-covidien-beats-the-street-by-a-nickel/45401#comments</comments>
		<pubDate>Fri, 30 Jul 2010 21:24:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien plc]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45401</guid>
		<description><![CDATA[Ireland-based healthcare product maker Covidien plc (COV) reported third-quarter fiscal 2010 results with adjusted (excluding one-time items such as restructuring charges and tax-related adjustments) earnings per share of 85 cents beating the Zacks Consensus Estimate of 80 cents and exceeding the year-ago quarter earnings of 74 cents. Net income from continued operation sailed 29% year-over-year to $352 million (or 70 cents a share), favored by higher medical devices sales and lower research and development expenses. Revenues Net sales edged up 2% year-over-year to $2.56 billion, but missed the Zacks Consensus Estimate of $2.62 billion as incremental revenues from medical devices were marred by the decline in the pharmaceuticals division. Segment Analysis Medical Devices revenues grew 6% year-over-year to $1.54 billion on the back of double-digit revenue expansions across Oximetry and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/30/cov-covidien-beats-the-street-by-a-nickel/45401/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International to Recall Infusion Pumps</title>
		<link>http://www.stockbloghub.com/2010/07/15/bax-baxter-international-to-recall-infusion-pumps/43457</link>
		<comments>http://www.stockbloghub.com/2010/07/15/bax-baxter-international-to-recall-infusion-pumps/43457#comments</comments>
		<pubDate>Thu, 15 Jul 2010 15:21:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=43457</guid>
		<description><![CDATA[Medical product giant Baxter International Inc. (BAX) has decided to recall all of its Colleague infusion pumps in the U.S. over the next two years. The decision is based on the final order of the U.S. Food and Drug Administration (FDA). Baxter will either offer the Colleague infusion pump owners a no-cost replacement or offer them a refund. Under the replacement plan, the company is permitting its customers to exchange its Sigma Spectrum next-generation infusion pumps for Colleague infusion pumps without a charge. Otherwise, the customers will get the pump’s depreciated value (minimum of $1,500 and $3,000 for single-channel and triple-channel pump, respectively) or the purchase price, whichever is lower. Moreover, Baxter will offer services and support to customers who continue using the Colleague pumps during the two-year transition period ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/15/bax-baxter-international-to-recall-infusion-pumps/43457/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GPRO) Gen-Probe Invests $50 Million in Pacific Biosciences</title>
		<link>http://www.stockbloghub.com/2010/07/05/gpro-gen-probe-invests-50-million-in-pacific-biosciences/40813</link>
		<comments>http://www.stockbloghub.com/2010/07/05/gpro-gen-probe-invests-50-million-in-pacific-biosciences/40813#comments</comments>
		<pubDate>Mon, 05 Jul 2010 16:14:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Research Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Gen-Probe Inc.]]></category>
		<category><![CDATA[GPRO]]></category>
		<category><![CDATA[NAT]]></category>
		<category><![CDATA[Nordic American Tanker Shipping Limited]]></category>
		<category><![CDATA[SMRT]]></category>
		<category><![CDATA[Stein Mart Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=40813</guid>
		<description><![CDATA[Diagnostic product maker Gen-Probe Inc (GPRO) has made a $50 million strategic investment in privately-held DNA sequencing firm Pacific Biosciences (PacBio). The companies will collaborate on developing products based on their proprietary technologies. Per the deal, the companies will combine their efforts to develop new clinical diagnostic systems, leveraging PacBio&#8217;s Single Molecule Real Time (SMRT) DNA sequencing technology platform and Gen-Probe&#8217;s diagnostic expertise. They will initially collaborate for up to 30 months with the goal of building a long-term relationship and improving diagnostic capabilities. Moreover, the companies will buy each other&#8217;s products on preferred terms of trade. California-based Gen-Probe has been a pioneer in the commercial and scientific development of nucleic acid testing (NAT) for the diagnosis of infectious diseases. The company sells its products in the clinical diagnostic as well ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/05/gpro-gen-probe-invests-50-million-in-pacific-biosciences/40813/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Recalls Products</title>
		<link>http://www.stockbloghub.com/2010/05/19/bax-baxter-international-recalls-products/37672</link>
		<comments>http://www.stockbloghub.com/2010/05/19/bax-baxter-international-recalls-products/37672#comments</comments>
		<pubDate>Thu, 20 May 2010 00:29:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HALO]]></category>
		<category><![CDATA[Halozyme Therapeutics Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37672</guid>
		<description><![CDATA[Baxter International Inc. (BAX) has recently initiated a voluntary recall of all lots of its Hylenex recombinant as a result of glass particles found in vials of the product. Hylenex increases the absorption of fluids to boost injected drugs and for fluids and drugs administered under the skin. Baxter licenses the Hylenex recombinant technology from Halozyme Therapeutics Inc. (HALO). The company has the exclusive rights to market and sell Hylenex recombinant globally. Hylenex recombinant is a standalone formulation of recombinant human hyaluronidase. The product was launched in the United States in October 2009 for use in pediatric rehydration. Baxter is working with Halozyme Therapeutics to investigate the root cause of the issue and rectify the same. The company has not reported any customer complaints regarding the issue till date. We ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/19/bax-baxter-international-recalls-products/37672/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Review &#8211; May 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/05/11/mdt-medical-devices-stock-review-may-2010-industry-outlook/36750</link>
		<comments>http://www.stockbloghub.com/2010/05/11/mdt-medical-devices-stock-review-may-2010-industry-outlook/36750#comments</comments>
		<pubDate>Tue, 11 May 2010 21:55:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36750</guid>
		<description><![CDATA[The global medical devices industry is fairly large, with annual worldwide sales in 2009 in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different categories such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices, Healthcare IT, etc. We recommend companies providing life-sustaining products to investors in the medical devices space. These companies provide a strong recurring stream of revenues as patients are unable to forego these products due to their life-sustaining nature. Furthermore, investors should allocate funds to companies with high-earnings-quality profiles. Large companies with a wide portfolio of products are also better poised for improved returns. These companies have a greater capability of withstanding a downturn in the economy. We advise investors to avoid companies that have grown historically through ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/11/mdt-medical-devices-stock-review-may-2010-industry-outlook/36750/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Analyst Downgrades the Stock</title>
		<link>http://www.stockbloghub.com/2010/05/05/bax-baxter-international-analyst-downgrades-the-stock/36271</link>
		<comments>http://www.stockbloghub.com/2010/05/05/bax-baxter-international-analyst-downgrades-the-stock/36271#comments</comments>
		<pubDate>Wed, 05 May 2010 20:51:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36271</guid>
		<description><![CDATA[We recently downgraded Baxter International Inc. (BAX) to “Underperform&#8221; with a target price of $41 based on a P/E of roughly 10.4x our fiscal 2010 EPS estimate of $3.95. The company faces significant product recall issues and has also lowered its sales, earnings per share and cash flow outlook for fiscal 2010. This prompted us to downgrade the stock. Baxter recently decided to recall its COLLEAGUE infusion pumps in the U.S. due to remediation of these devices. The decision is based on the judgment of the U.S. Food and Drug Administration (FDA) pronounced in June 2006. In June 2006, Baxter entered into a consent decree with FDA under which it has been pursuing remediation of COLLEAGUE infusion pumps. The company will work with the FDA in ensuring that patients get ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/05/bax-baxter-international-analyst-downgrades-the-stock/36271/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Becton, Dickinson and Company Earnings Tops Estimate</title>
		<link>http://www.stockbloghub.com/2010/04/29/bdx-becton-dickinson-and-company-earnings-tops-estimate/35498</link>
		<comments>http://www.stockbloghub.com/2010/04/29/bdx-becton-dickinson-and-company-earnings-tops-estimate/35498#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:07:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35498</guid>
		<description><![CDATA[Becton, Dickinson and Company (BDX) reported second quarter fiscal 2010 earnings per share of $1.27, surpassing the Zacks Consensus Estimate of $1.23 and the year-ago earnings of $1.17. Sales Total revenues in the second quarter increased 7.0% year over year to $1.845 billion. Excluding foreign currency translation, total revenues increased 6.6% year over year. Growth was registered across all business segments. BD Medical revenues increased 9.7% year over year to $967 million. Growth can be attributed to higher sales of Pharmaceutical Systems and Diabetes Care products. BD Diagnostics revenues increased 3.0% year over year to $556 million. Growth was primarily due to higher demand for the company’s cancer and STD products. BD Biosciences sales increased 6.0% year over year to $322 million due to higher demand for the company’s Cell ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/bdx-becton-dickinson-and-company-earnings-tops-estimate/35498/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Wins New Customer Nassau University Medical Center</title>
		<link>http://www.stockbloghub.com/2010/04/18/masi-masimo-wins-new-customer-nassau-university-medical-center/34100</link>
		<comments>http://www.stockbloghub.com/2010/04/18/masi-masimo-wins-new-customer-nassau-university-medical-center/34100#comments</comments>
		<pubDate>Mon, 19 Apr 2010 01:40:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34100</guid>
		<description><![CDATA[Masimo Corp. (MASI) recently reported that its new customer, Nassau University Medical Center (NUMC), has completed its system-wide conversion to Masimo SET pulse oximetry technology. The conversion allows clinicians to monitor NUMC patients non-invasively using the latest pulse oximetry technology. This in turn provides real time data for vital parameters that aid clinicians in faster and accurate patient treatments. Masimo SET pulse oximetry enables clinicians to continuously and non-invasively measure multiple blood constituents that previously required invasive procedures. The multiple blood constituents measured are total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), oxyhemoglobin (SpO2), methemoglobin (SpMet), acoustic respiration rate (RRa), pulse rate (PR), and perfusion index (PI), etc. Masimo SET pulse oximetry eliminates the need to draw blood and wait for results. This helps physicians to immediately detect and treat ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/18/masi-masimo-wins-new-customer-nassau-university-medical-center/34100/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Posts Encouraging Clinical Study Results</title>
		<link>http://www.stockbloghub.com/2010/04/14/bax-baxter-international-posts-encouraging-clinical-study-results/33715</link>
		<comments>http://www.stockbloghub.com/2010/04/14/bax-baxter-international-posts-encouraging-clinical-study-results/33715#comments</comments>
		<pubDate>Wed, 14 Apr 2010 21:11:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33715</guid>
		<description><![CDATA[Baxter International Inc. (BAX) recently produced encouraging results of its 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D (Immune Globulin Intravenous [Human]) for mild-to-moderate Alzheimer’s disease. The clinical trial measures three key parameters: cognitive, functional and neuroimaging. All these parameters produced positive data. The Phase II clinical study enrolled 24 patients in the U.S. with mild-to-moderate Alzheimer’s disease. They were randomly assigned to receive GAMMAGARD (16 patients) or saline placebo (8 patients) for six months. After six months, eight patients who were initially receiving placebo were given various doses of GAMMAGARD. The other sixteen were given GAMMAGARD uninterrupted for 18 months. The functional parameter was measured by the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change rating (ADCS-CGIC) and cognitive was measured using the Alzheimer’s Disease Assessment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/bax-baxter-international-posts-encouraging-clinical-study-results/33715/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Receives FDA Approval for TachoSil</title>
		<link>http://www.stockbloghub.com/2010/04/07/bax-baxter-international-receives-fda-approval-for-tachosil/33068</link>
		<comments>http://www.stockbloghub.com/2010/04/07/bax-baxter-international-receives-fda-approval-for-tachosil/33068#comments</comments>
		<pubDate>Wed, 07 Apr 2010 22:59:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33068</guid>
		<description><![CDATA[Baxter International Inc. (BAX) and Nycomed recently received the U.S. Food and Drug Administration (FDA) approval of TachoSil, an absorbable fibrin sealant patch that can be used in addition to hemostasis to stop bleeding during cardiovascular surgeries. Baxter expects to launch the product in the U.S. in the second half of 2010. TachoSil is the first and only adjunctive hemostatic agent of its kind that is available in the U.S. TachoSil combines a collagen patch with a coating of human coagulation factors and can be applied directly to the bleeding area in dry or wet form. This addresses the biggest challenge of bleeding in cardiovascular surgeries. TachoSil is a patented Nycomed product and Baxter has exclusive rights to market and distribute the product in the U.S. TachoSil is presently available ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/07/bax-baxter-international-receives-fda-approval-for-tachosil/33068/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Analysts Maintain Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/03/17/masi-masimo-analysts-maintain-neutral-rating/30936</link>
		<comments>http://www.stockbloghub.com/2010/03/17/masi-masimo-analysts-maintain-neutral-rating/30936#comments</comments>
		<pubDate>Wed, 17 Mar 2010 19:33:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30936</guid>
		<description><![CDATA[We continue to maintain our ‘Neutral’ rating on Masimo Corp. (MASI) with a target price of $28 based on a P/E of 28.0x our fiscal 2010 EPS estimate of $1. The company’s fourth quarter fiscal 2009 results reflect a mixed trend. Masimo reported fourth-quarter earnings per share of 23 cents, surpassing the Zacks Consensus Estimate of 22 cents. However, earnings was lower than the year-ago figure of 24 cents. For fiscal 2009, earnings per share was 88 cents, in line with the Zacks Consensus Estimate and higher than 78 cents, a year-ago. Total revenue in the fourth quarter increased 11% year over year to $92.6 million. Product revenue increased 12% year over year to $80.5 million. Royalty revenue increased 6% year over year to $12.2 million. Growth in product revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/17/masi-masimo-analysts-maintain-neutral-rating/30936/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Becton, Dickinson and Company Recalls Catheters</title>
		<link>http://www.stockbloghub.com/2010/02/10/bdx-becton-dickinson-and-company-recalls-catheters/27580</link>
		<comments>http://www.stockbloghub.com/2010/02/10/bdx-becton-dickinson-and-company-recalls-catheters/27580#comments</comments>
		<pubDate>Wed, 10 Feb 2010 20:52:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27580</guid>
		<description><![CDATA[Becton, Dickinson and Company (BDX) recently started expanding the recall of its catheters as a result of a manufacturing problem that could cause fatal embolisms or blood leakage. Becton is recalling its defective Q-Syte Luer Access Devices and Nexiva Closed IV Catheter Systems. The company started the initial recall of these products on Oct 28, 2009. Becton is in constant touch with the U.S. Food and Drug Administration (FDA) and worldwide health agencies to coordinate the recall. The Nexiva products have two Q-Syte devices within the package that could be affected. The Q-Syte devices are used with intravenous systems. Becton has already recalled roughly 2.8 million Q-Syte and 2.9 million Nexiva units containing 5 million Q-Syte devices. Becton, Dickinson has identified the root cause of the manufacturing problem and has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/10/bdx-becton-dickinson-and-company-recalls-catheters/27580/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Downgraded to Neutral</title>
		<link>http://www.stockbloghub.com/2010/02/05/bax-baxter-international-downgraded-to-neutral/27192</link>
		<comments>http://www.stockbloghub.com/2010/02/05/bax-baxter-international-downgraded-to-neutral/27192#comments</comments>
		<pubDate>Sat, 06 Feb 2010 00:24:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27192</guid>
		<description><![CDATA[We recently downgraded Baxter International Inc. (BAX) to Neutral. The stock was assigned a target price of $59 based on an approximate P/E multiple of 13.9x our fiscal 2010 earnings estimate of $4.25. Baxter recently reported fourth quarter and fiscal 2009 results. For the fourth quarter, earnings per share were $1.03, in line with the Zacks Consensus Estimate and higher than the year-ago earnings of 91 cents. For full fiscal 2009, earnings per share were $3.80, again in line with the Zacks Consensus Estimate and higher than the year-ago earnings of $3.38. Earnings Estimate Revision Trend and Zacks Rank The earnings estimate revision for Baxter has demonstrated a down trend in the past 30 days. During the period, seven out of eleven analysts downgraded their earnings estimates while only two ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/05/bax-baxter-international-downgraded-to-neutral/27192/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Becton, Dickinson and Company Beats Expectations &#8211; Bumps Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/02/bdx-becton-dickinson-and-company-beats-expectations-bumps-estimates/26717</link>
		<comments>http://www.stockbloghub.com/2010/02/02/bdx-becton-dickinson-and-company-beats-expectations-bumps-estimates/26717#comments</comments>
		<pubDate>Tue, 02 Feb 2010 18:26:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26717</guid>
		<description><![CDATA[We recently reiterated our Neutral rating on Becton, Dickinson and Company (BDX) with a target price of $78 based on a P/E of approximately 15.3x our fiscal 2010 EPS estimate of $5.10. Becton recently reported first quarter fiscal 2010 results. Earnings per share of $1.30 easily beats the Zacks Consensus Estimate of $1.20 and the year-ago earnings of $1.26. The company also reported an expansion in its top-line with growth across all major business segments. BD Medical revenues increased 16% year over year to $1.019 billion. Growth can be attributed to higher sales of Medical Surgical, Pharmaceutical Systems and Diabetes Care products. BD Diagnostics revenues increased 10% year over year to $595 million. Growth was primarily due to higher demand for the company’s safety-engineered devices and infectious disease testing systems. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/02/bdx-becton-dickinson-and-company-beats-expectations-bumps-estimates/26717/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDRX) Medical Devices Stock Review &#8211; Feburary 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/02/01/mdrx-medical-devices-stock-review-feburary-2010-industry-outlook/26636</link>
		<comments>http://www.stockbloghub.com/2010/02/01/mdrx-medical-devices-stock-review-feburary-2010-industry-outlook/26636#comments</comments>
		<pubDate>Mon, 01 Feb 2010 22:23:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare Information Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Allscripts-Misys Healthcare Solutions Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Hanger Orthopedic Group Inc.]]></category>
		<category><![CDATA[HGR]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[MDRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[OMCL]]></category>
		<category><![CDATA[Omnicell Inc.]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26636</guid>
		<description><![CDATA[The global medical devices industry is fairly large, with annual worldwide sales in excess of $200 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different categories such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices, Healthcare IT, etc. We recommend companies providing life-sustaining products to investors in the medical devices space. These companies provide a strong recurring stream of revenues as patients are unable to forego these products due to their life-sustaining nature. Furthermore, investors should allocate funds to companies with high-earnings-quality profiles. Large companies with a wide portfolio of products are also better poised for improved returns. These companies have a greater capability of withstanding a downturn in the economy. Another area which is interestingly poised for growth these days is Healthcare IT. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/01/mdrx-medical-devices-stock-review-feburary-2010-industry-outlook/26636/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Becton Dickinson and Company Surpasses Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/28/bdx-becton-dickinson-and-company-surpasses-consensus-estimates/26288</link>
		<comments>http://www.stockbloghub.com/2010/01/28/bdx-becton-dickinson-and-company-surpasses-consensus-estimates/26288#comments</comments>
		<pubDate>Thu, 28 Jan 2010 20:28:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26288</guid>
		<description><![CDATA[Becton, Dickinson and Company (BDX) reported first quarter fiscal 2010 earnings per share of $1.30, surpassing the Zacks Consensus Estimate of $1.20 and the year-ago earnings of $1.25. Total Revenues Total revenues in the first quarter increased 12% year over year to $1.917 billion. Excluding the foreign currency translation (FX), total revenues increased 9% year over year. Growth was registered across all major business segments. BD Medical revenues increased 16% year over year to $1.019 billion. Growth can be attributed to higher sales of Medical Surgical, Pharmaceutical Systems and Diabetes Care products. BD Diagnostics revenues increased 10% year over year to $595 million. Growth was primarily due to higher demand for the company’s safety-engineered devices and infectious disease testing systems. BD Biosciences revenues were approximately flat year over year at ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/28/bdx-becton-dickinson-and-company-surpasses-consensus-estimates/26288/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Reports Earnings In-Line</title>
		<link>http://www.stockbloghub.com/2010/01/28/bax-baxter-international-reports-earnings-in-line/26319</link>
		<comments>http://www.stockbloghub.com/2010/01/28/bax-baxter-international-reports-earnings-in-line/26319#comments</comments>
		<pubDate>Thu, 28 Jan 2010 20:22:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26319</guid>
		<description><![CDATA[Baxter International Inc. (BAX) reported financial results for the fourth quarter and full fiscal 2009. For the fourth quarter, earnings per share were $1.03, in line with the Zacks Consensus Estimate and higher than the year-ago earnings of 91 cents. For full fiscal 2009, earnings per share were $3.80, again in line with the Zacks Consensus Estimate and greater than the year-ago earnings of $3.38. Quarterly results Net sales in the reported quarter increased 11% year over year to roughly $3.5 billion. Excluding the foreign currency translation (FX), net sales increased 6% year over year. Baxter reported sales growth across all its business segments. BioScience revenues increased 12% year over year to $1.5 billion. Growth was due to higher sales of recombinant products (including ADVATE), antibody therapies, biosurgery products and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/28/bax-baxter-international-reports-earnings-in-line/26319/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Corporation Announces Positive Results From Clinical Study</title>
		<link>http://www.stockbloghub.com/2010/01/25/masi-masimo-corporation-announces-positive-results-from-clinical-study/25894</link>
		<comments>http://www.stockbloghub.com/2010/01/25/masi-masimo-corporation-announces-positive-results-from-clinical-study/25894#comments</comments>
		<pubDate>Mon, 25 Jan 2010 20:30:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25894</guid>
		<description><![CDATA[Masimo Corporation (MASI) recently announced positive results form its 21-month clinical study on the impact of the Masimo Patient SafetyNet remote monitoring and clinician notification system. Results indicated that continuous pulse oximetry monitoring and clinician notification in post-surgical patients on the general floor leads to a significant drop in key clinical outcome measures, such as 65% fewer rescue events, 48% fewer ICU transfers and reduced annualized ICU time by 135 days. Masimo Patient SafetyNet combines the performance of Masimo SET pulse oximetry at the point of care with remote monitoring and wireless clinician notification via pager. This is the first study on adults using Masimo SET pulse oximetry technology that demonstrated improved patient safety while reducing the cost. Masimo SET pulse oximetry enables clinicians to continuously and non-invasively measure multiple ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/25/masi-masimo-corporation-announces-positive-results-from-clinical-study/25894/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Corporation Can Now Earn While Patients Test Device Effectiveness</title>
		<link>http://www.stockbloghub.com/2010/01/05/masi-masimo-corporation-can-now-earn-while-patients-test-device-effectiveness/24122</link>
		<comments>http://www.stockbloghub.com/2010/01/05/masi-masimo-corporation-can-now-earn-while-patients-test-device-effectiveness/24122#comments</comments>
		<pubDate>Tue, 05 Jan 2010 18:29:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24122</guid>
		<description><![CDATA[Masimo Corporation (MASI) has recently received a new Current Procedural Terminology (CPT) code from the American Medical Association, 88738, for its noninvasive hemoglobin (SpHb) measurement. Medicare has priced the new CPT code at $7.19 on its 2010 Medicare Clinical Laboratory Fee Schedule. The new pricing has been effective since Jan 1, 2010. The new CPT code is an important milestone for Masimo. It will now permit health care providers to bill and receive payments from Medicare when testing eligible patients. This in turn will encourage them to use Masimo’s SpHb measurement  devices that will expand the company’s top line. Masimo develops, manufactures and markets a family of non-invasive blood monitoring systems that consist of a monitor, circuit board and sensors. The systems are primarily used to monitor blood oxygen saturation ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/05/masi-masimo-corporation-can-now-earn-while-patients-test-device-effectiveness/24122/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Corporation in Expansion Mode</title>
		<link>http://www.stockbloghub.com/2009/12/29/masi-masimo-corporation-in-expansion-mode/23870</link>
		<comments>http://www.stockbloghub.com/2009/12/29/masi-masimo-corporation-in-expansion-mode/23870#comments</comments>
		<pubDate>Wed, 30 Dec 2009 01:04:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien plc]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23870</guid>
		<description><![CDATA[Masimo Corp. (MASI) recently announced the expansion of its corporate campus in Irvine, California with the addition of an adjacent 32,000 sq. ft. building. This is the company&#8217;s third building on its corporate campus. Masimo stated that the new building is expected to accommodate more than 200 employees. The expansion of Masimo’s corporate headquarters will further strengthen its engineering, sales and administrative functions in 2010. These are required to accommodate the increasing demand for its breakthrough medical technologies Incorporatedluding the expansion of its Masimo Rainbow SET Pulse CO-Oximetry and new Acoustic Monitoring business. The current year alone has seen more than 150 hospitals throughout the world adapt the company’s advanced pulse oximetry technology. As a reminder, earlier this month, Masimo’s new customer, Brookdale University Hospital and Medical Center in Brooklyn, New ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/29/masi-masimo-corporation-in-expansion-mode/23870/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Completes Conversion of New Customer</title>
		<link>http://www.stockbloghub.com/2009/12/14/masi-masimo-completes-conversion-of-new-customer/22770</link>
		<comments>http://www.stockbloghub.com/2009/12/14/masi-masimo-completes-conversion-of-new-customer/22770#comments</comments>
		<pubDate>Tue, 15 Dec 2009 01:30:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22770</guid>
		<description><![CDATA[Masimo Corp. (MASI) reported that its new customer, Brookdale University Hospital and Medical Center in Brooklyn, New York, has completed its system-wide conversion to Masimo SET pulse oximetry technology. Brookdale has also installed Masimo’s first-ever continuous and noninvasive hemoglobin monitoring (SpHb) technology in its select care settings. This allows clinicians to detect and treat chronic or acute anemia earlier, more effectively manage blood transfusions for their patients and identify internal bleeding quicker. The Brookdale University Hospital and Medical Center is one of the largest voluntary nonprofit teaching hospitals in Brooklyn and a New York State Department of Health (DOH) designated Stroke Center. Masimo SET pulse oximetry enables clinicians to continuously and non-invasively measure multiple blood constituents that previously required invasive procedures. The multiple blood constituents measured are total hemoglobin (SpHb), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/14/masi-masimo-completes-conversion-of-new-customer/22770/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Becton, Dickinson and Co Receives FDA Clearance</title>
		<link>http://www.stockbloghub.com/2009/12/09/bdx-becton-dickinson-and-co-receives-fda-clearance/22376</link>
		<comments>http://www.stockbloghub.com/2009/12/09/bdx-becton-dickinson-and-co-receives-fda-clearance/22376#comments</comments>
		<pubDate>Wed, 09 Dec 2009 23:23:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Capital Trust]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22376</guid>
		<description><![CDATA[Becton, Dickinson and Co. (BDX) recently announced that BD Diagnostics, a segment of BDX, has received U.S. Food and Drug Administration (FDA) clearance to utilize its BD ProbeTec Chlamydia trachomatis (CT) Qx and BD ProbeTec Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected from women&#8217;s routine liquid-based Pap testing for cervical cancer screening. The BD ProbeTec Qx Amplified DNA Assays are the first to receive FDA clearance for gynecological specimens collected and transported for Pap testing in cervical cancer. Pap testing is one of the two leading types of liquid-based cytology (LBC) preservative media on the market today. Pap Testing uses detachable-head collection devices that ensure that 100% of collected cells are sent to the laboratory for analysis. The ability to test for chlamydia and gonorrhea while screening ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/09/bdx-becton-dickinson-and-co-receives-fda-clearance/22376/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAX) Baxter International Gets H1N1 Vaccine Order</title>
		<link>http://www.stockbloghub.com/2009/12/04/bax-baxter-international-gets-h1n1-vaccine-order/22060</link>
		<comments>http://www.stockbloghub.com/2009/12/04/bax-baxter-international-gets-h1n1-vaccine-order/22060#comments</comments>
		<pubDate>Sat, 05 Dec 2009 01:10:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22060</guid>
		<description><![CDATA[Baxter International Inc. (BAX) recently received another order for 10,000 H1N1 vaccines, commonly known as &#8220;swine flu,&#8221; from Slovenia. The order is worth $158,700 (105,000 euros). It is estimated that the number of vaccines ordered is sufficient to cover 5,000 people in the country. Slovenia has also decided to purchase a total of 1.3 million units of H1N1 vaccines from the British arm of GlaxoSmithKline plc (GSK) and the Swiss arm of Novartis AG (NVS) by the end of Jan. 2010. This would cost Slovenia roughly 14 million euros. The new order will help Baxter boost its top-line. Baxter sees a multiyear opportunity in H1N1 vaccines. The company expects to recognize $30 million to $40 million in revenues from H1N1 vaccines in the fourth quarter of 2009. Baxter has not ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/04/bax-baxter-international-gets-h1n1-vaccine-order/22060/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Corporation Earns FDA New Product Approval</title>
		<link>http://www.stockbloghub.com/2009/12/02/masi-masimo-corporation-earns-fda-new-product-approval/21799</link>
		<comments>http://www.stockbloghub.com/2009/12/02/masi-masimo-corporation-earns-fda-new-product-approval/21799#comments</comments>
		<pubDate>Wed, 02 Dec 2009 22:21:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21799</guid>
		<description><![CDATA[Masimo Corporation (MASI) recently received the U.S. Food and Drug Administration (FDA) approval for its new product, Masimo Rainbow SET Acoustic Monitoring. The new product enables noninvasive and continuous monitoring of human respiration rate (RRa). The data provided is accurate, easy-to-use, and thereby enhances patient compliance. With the approval, Masimo expects to launch the product in a limited market release in the U.S. in this month. The new product enables earlier detection of respiratory compromise and patient distress. This is especially important for post-surgical patients receiving patient-controlled analgesia for pain management. It is seen that these patients often suffer from respiratory problems due to sedation, which can result in serious injury or even death. Masimo Rainbow SET Acoustic Monitoring also eliminates the lack of accuracy and patient compliance issues prevalent ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/02/masi-masimo-corporation-earns-fda-new-product-approval/21799/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MASI) Masimo Corporation Renews Deal with Advocate Health Care</title>
		<link>http://www.stockbloghub.com/2009/11/29/masi-masimo-corporation-renews-deal-with-advocate-health-care/21455</link>
		<comments>http://www.stockbloghub.com/2009/11/29/masi-masimo-corporation-renews-deal-with-advocate-health-care/21455#comments</comments>
		<pubDate>Mon, 30 Nov 2009 04:25:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21455</guid>
		<description><![CDATA[Masimo Corporation (MASI) announced that one of its prominent customers, Advocate Health Care, has recently renewed its multi-year, system-wide contract for Masimo SET pulse oximetry technology. Advocate Health Care is Illinois&#8217; largest and one of the top ten health care providers in the U.S. It has more than 200 patient-care sites across Chicago. Financial terms of the contract have not been disclosed. Advocate Health Care has been Masimo’s customer since 2001. The contract enables Masimo to support the pulse oximetry needs of more than 200 sites of Advocate Health Care. This will in turn boost Masimo’s top-line. Masimo Corporation develops, manufactures and markets a family of non-invasive blood monitoring systems that consist of a monitor, circuit board and sensors. The systems are primarily used to monitor blood oxygen saturation levels ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/29/masi-masimo-corporation-renews-deal-with-advocate-health-care/21455/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Becton, Dickinson and Company Acquires HandyLab</title>
		<link>http://www.stockbloghub.com/2009/11/23/bdx-becton-dickinson-and-company-acquires-handylab/21106</link>
		<comments>http://www.stockbloghub.com/2009/11/23/bdx-becton-dickinson-and-company-acquires-handylab/21106#comments</comments>
		<pubDate>Mon, 23 Nov 2009 16:34:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21106</guid>
		<description><![CDATA[Becton, Dickinson and Company (BDX) recently completed the acquisition of HandyLab, Inc, an Ann Arbor, Michigan-based company that develops and manufactures automation platforms and molecular diagnostic assays. The transaction costs Becton $275 million. The acquisition enables Becton to develop and commercialize its BD GeneOhm molecular assays on the HandyLab Jaguar platform, the first fully integrated molecular diagnostic system. The HandyLab instrumentation technology is considered to be an industry leading molecular diagnostic automation platform. With the acquisition, Becton plans to market its BD GeneOhm molecular assays as the new BD Max system. Becton is a global leader in the treatment of healthcare associated infections (HAI). With growing concerns over HAI, hospitals are expanding their screening and testing programs and require automation systems to support their evolving needs. Becton addresses HAI issues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/23/bdx-becton-dickinson-and-company-acquires-handylab/21106/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CFN) CareFusion Corporation Enters Agreement with Masimo</title>
		<link>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535</link>
		<comments>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535#comments</comments>
		<pubDate>Sat, 14 Nov 2009 22:12:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[MASI]]></category>
		<category><![CDATA[Masimo Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20535</guid>
		<description><![CDATA[CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry technology in CareFusion infusion and respiratory products, which are presently under development. The agreement enables CareFusion’s future infusion and respiratory products to non-invasively and continuously measure multiple blood constituents to more accurately assess dyshemoglobins affecting oxygenation, predict fluid responsiveness, and provide earlier identification of respiratory compromise. CareFusion’s ventilators and infusion pumps facilitate earlier detection, diagnosis and treatment of potentially life-threatening conditions by accessing total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), and PVI for fluid responsiveness, in addition to oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate. CareFusion is a medical technology company formed recently by the spin-off of the Clinical and Medical Products business ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/masi-carefusion-corporation-enters-agreement-with-masimo/20535/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BDX) Becton, Dickinson and Co Reports Strong Results</title>
		<link>http://www.stockbloghub.com/2009/11/08/bdx-becton-dickinson-and-co-reports-strong-results/19799</link>
		<comments>http://www.stockbloghub.com/2009/11/08/bdx-becton-dickinson-and-co-reports-strong-results/19799#comments</comments>
		<pubDate>Mon, 09 Nov 2009 03:21:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19799</guid>
		<description><![CDATA[Becton, Dickinson and Co. (BDX) reported strong fourth quarter and full fiscal 2009 results. For the fourth quarter, earnings per share were $1.25, beating the Zacks Consensus Estimate by a cent and the year-ago earnings by 14 cents. For fiscal 2009, earnings per share came in at $4.95, which was below the Zacks Consensus Estimate by a cent but surpassed the year-ago earnings by 53 cents. Quarterly Results Revenues for the reported quarter came in at $1.9 billion as against $1.81 billion in the year-ago quarter, representing an increase of 4.7%. However, revenues grew 8%. excluding the unfavorable impact from foreign currency translation. In terms of business segments, worldwide BD Medical revenues increased 8.2% to $1.01 billion in the quarter. The growth was driven by strong sales of Pharmaceutical Systems ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/08/bdx-becton-dickinson-and-co-reports-strong-results/19799/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

